SCHEMBL761706

SCHEMBL761706

CC(C)C(=O)NCCc1c[nH]c2ccccc12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 6/20 0.75
KMT2A Q03164 6/20 0.75
TSHR P16473 2/20 0.75
ALDH1A1 P00352 2/20 0.75
MAPT P10636 2/20 0.75
KDM4E B2RXH2 1/20 0.75
CYP3A4 P08684 1/20 0.75
ALOX15 P16050 1/20 0.75
MAPK1 P28482 1/20 0.75
HSD17B10 Q99714 1/20 0.75
TDP1 Q9NUW8 1/20 0.75
LMNA P02545 1/20 0.74
CYP1A2 P05177 1/20 0.74
PKM P14618 1/20 0.74
CYP2C19 P33261 1/20 0.74
BLM P54132 1/20 0.74
SPR P35270 1/20 0.70
MMP9 P14780 1/20 0.67
AANAT Q16613 1/20 0.67
NPC1 O15118 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17037428 0.91 MEN1 (0.70) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL18595162 0.89 MEN1 (0.76) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL7677879 0.88 MEN1 (0.67) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL9118606 0.88 MEN1 (0.71) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL6365945 0.86 MEN1 (0.65) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL15145390 0.86 CTSC (0.71) MEN1KMT2ATSHRALDH1A1MAPT
Nb-Acetyltryptamine SCHEMBL468850 0.85 MEN1 (1.00) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL10554058 0.85 MEN1 (0.64) MEN1KMT2ATSHRALDH1A1MAPT
SCHEMBL7612467 0.85 MEN1 (0.64) MEN1KMT2ATSHRALDH1A1MAPT
Nb-Acetyltryptamine SCHEMBL29669230 0.84 MEN1 (0.97) MEN1KMT2ATSHRALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240218374-A1 Nucleic Acid Compounds That Bind Coronavirus Proteins SOMALOGIC OPERATING CO., INC. (US) 2024-07-04 US disclosed
US-20240218374-A1 Nucleic Acid Compounds That Bind Coronavirus Proteins SOMALOGIC OPERATING CO., INC. (US) 2024-07-04 US disclosed
US-20230193287-A1 Nucleic Acid Compounds for Binding Growth Differentiation Factor 11 SOMALOGIC OPERATING CO., INC. (US) 2023-06-22 US disclosed
US-20230024434-A1 Methods for Developing Personalized Drug Treatment Plans and Targeted Drug Development Based on Proteomic Profiles SOMALOGIC, INC. (US) 2023-01-26 US disclosed
US-11111495-B2 Method for generating aptamers with improved off-rates SOMALOGIC, INC. (US) 2021-09-07 US disclosed
US-10889556-B2 Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2021-01-12 US disclosed
US-20190330634-A1 Method for Generating Aptamers with Improved Off-Rates SOMALOGIC OPERATING CO., INC. 2019-10-31 US disclosed
US-20190106398-A1 COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-04-11 US disclosed
US-20180187197-A1 Multiaptamer Target Detection SOMALOGIC OPERATING CO., INC. 2018-07-05 US disclosed
US-9994857-B2 PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders SOMALOGIC, INC. (US) 2018-06-12 US disclosed
US-7947447-B2 Method for generating aptamers with improved off-rates SOMALOGIC, INC. (US) 2011-05-24 US disclosed
US-7947447-B2 Method for generating aptamers with improved off-rates SOMALOGIC, INC. (US) 2011-05-24 US disclosed
US-20110082286-A1 Method for Generating Aptamers with Improved Off-Rates SOMALOGIC, INC. (US) 2011-04-07 US disclosed
US-20110082286-A1 Method for Generating Aptamers with Improved Off-Rates SOMALOGIC, INC. (US) 2011-04-07 US disclosed
WO-2011006075-A1 METHOD FOR GENERATING APTAMERS WITH IMPROVED OFF-RATES SOMALOGIC, INC. (US) 2011-01-13 WO disclosed
US-7855054-B2 Multiplexed analyses of test samples SOMALOGIC, INC. (US) 2010-12-21 US disclosed
US-7855054-B2 Multiplexed analyses of test samples SOMALOGIC, INC. (US) 2010-12-21 US disclosed
US-20100105683-A1 COMPOUNDS USEFUL FOR INHIBITING CHK1 KEEGAN KATHLEEN S 2010-04-29 US disclosed
US-7608618-B2 Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 ICOS CORPORATION (US) 2009-10-27 US disclosed
US-20090131478-A1 Growth Hormone Secretagogues IPSEN PHARMA S.A.S. (FR) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106398-A1 COMPOSITIONS AND METHODS FOR INHIBITING INFLUENZA RNA POLYMERASE PA ENDONUCLEASE POLRMT, RNASE1, POLM MEN1 3312/4885KMT2A 1216/4885TSHR 3661/4885
US-20230193287-A1 Nucleic Acid Compounds for Binding Growth Differentiation Factor 11 MSTN, S100A11, IGF2BP1 MEN1 1586/4885KMT2A 3322/4885TSHR 512/4885
US-20100105683-A1 COMPOUNDS USEFUL FOR INHIBITING CHK1 CHEK1, PCNA, CHEK2 MEN1 1983/4885KMT2A 1546/4885TSHR 4083/4885
US-20110082286-A1 Method for Generating Aptamers with Improved Off-Rates DDX1, DDX3X, DDX18 MEN1 4259/4885KMT2A 1608/4885TSHR 817/4885
US-20240218374-A1 Nucleic Acid Compounds That Bind Coronavirus Proteins SARS1, RNGTT, PABPC1 MEN1 4651/4885KMT2A 3666/4885TSHR 3407/4885
US-20090131478-A1 Growth Hormone Secretagogues GHSR, GHRHR, GHITM MEN1 234/4885KMT2A 3668/4885TSHR 50/4885
US-10889556-B2 Compositions and methods for inhibiting influenza RNA polymerase PA endonuclease POLRMT, RNASE1, POLM MEN1 3312/4885KMT2A 1216/4885TSHR 3661/4885
US-20230024434-A1 Methods for Developing Personalized Drug Treatment Plans and Targeted Drug Development Based on Proteomic Profiles TTR, TPX2, FABP1 MEN1 4410/4885KMT2A 3305/4885TSHR 2563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.